Simon Pfisterer’s research group combines laboratory automation with cell biology, elucidating how genetic variants contribute to biological variability and how biological variability links to disease progression and treatment outcomes in dyslipidaemia and cardiovascular disease. With this approach he aims to disentangle the genetic complexity of dyslipidaemia and develop novel tools to improve the diagnosis and treatment of familial hypercholesterolaemia. 
Besides performing research at University of Helsinki, Simon Pfisterer co-founded the startup company Moncyte Ltd, which is developing novel precision medicine applications for dyslipidaemia.